Katerina Kappes

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

S. Jagannath, C. Cordon-Cardo, V. Simon, 2021, Cancer Cell.

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

S. Jagannath, C. Cordon-Cardo, M. Merad, 2021, Cancer Cell.

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2022, Journal of Hematology & Oncology.

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2022, Journal of Hematology & Oncology.

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

S. Jagannath, C. Cordon-Cardo, S. Almo, 2022, Cancer Cell.

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2022, Journal of Hematology & Oncology.

Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2023, Journal of Hematology & Oncology.

Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients

S. Jagannath, C. Cordon-Cardo, M. Merad, 2021, medRxiv.